Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial


This randomised, double-blind, placebo-controlled study was designed to evaluate the ability of the orally administered matrix metalloproteinase inhibitor, marimastat, to prolong survival in patients with non-resectable gastric and gastro-oesophageal adenocarcinoma. Three hundred and sixty-nine patients with histological proof of adenocarcinoma, who had… (More)
DOI: 10.1038/sj.bjc.6600310

8 Figures and Tables


  • Presentations referencing similar topics